Prospect of rindopepimut in the treatment of glioblastoma.

@article{Elsamadicy2017ProspectOR,
  title={Prospect of rindopepimut in the treatment of glioblastoma.},
  author={Aladine A. Elsamadicy and Pakawat Chongsathidkiet and Rupen Desai and Karolina I Woroniecka and Samuel Harrison Farber and Peter Edward Fecci and John H. Sampson},
  journal={Expert opinion on biological therapy},
  year={2017},
  volume={17 4},
  pages={507-513}
}
INTRODUCTION Rindopepimut (CDX-110) is a peptide vaccine that targets epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific epitope expressed in the most common and lethal primary malignant neoplasm of the brain - glioblastoma (GBM). Areas covered: The EGFRvIII mutation introduces an 801 base pair in-frame deletion of the extracellular domain of the transmembrane tyrosine kinase, resulting in constitutive kinase activity, amplification of cell growth, and inhibition of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…